Caris Life Sciences dual lists common shares on NYSE Texas
Caris Life Sciences announced the dual listing of its common stock on NYSE Texas, effective June 17, 2026. The company, currently listed on NASDAQ under the symbol CAI, aims to expand its public market presence through this strategic initiative.
*this image is generated using AI for illustrative purposes only.
Caris Life Sciences, a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, announced the dual listing of its common stock on NYSE Texas effective on June 17, 2026. This strategic move is designed to further expand the company's presence in the public markets.
The company's shares are currently listed on NASDAQ under the symbol CAI. By securing a dual listing, Caris Life Sciences seeks to enhance accessibility for investors and strengthen its market position.
Listing Details
The dual listing on NYSE Texas marks a significant milestone for Caris Life Sciences as it continues to grow its footprint in the financial markets. The following table outlines the key details of the listing:
| Exchange | Ticker Symbol | Effective Date |
|---|---|---|
| NASDAQ | CAI | Existing |
| NYSE Texas | CAI | June 17, 2026 |
Strategic Implications
This dual listing aligns with Caris Life Sciences' broader strategy to increase visibility and attract a diverse investor base. The move underscores the company's commitment to leveraging advanced AI and precision medicine to drive innovation in healthcare.
How will the dual listing impact Caris Life Sciences' liquidity and trading volume?
What criteria did NYSE Texas meet to attract Caris Life Sciences for this listing?
Will this move lead to increased institutional investment in the company?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
